A clinical study of DKN-01 in combination with KEYTRUDA® (pembrolizumab) patients with relapsed or refractory advanced esophagogastric adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs DKN 01 (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 13 Nov 2017 According to a Leap Therapeutics media release, the first patient has been dosed in this trial. Dr. Samuel Klempner, is an investigator on the study.
- 13 Nov 2017 Status changed from planning to recruiting, according to a Leap Therapeutics media release.
- 28 Jun 2017 New trial record